Use of adipsin/complement factor D in the treatment of metabolic related disorders
First Claim
Patent Images
1. A method of reducing body mass in an individual comprising administering to said individual a composition comprising a carrier and an Adipsin polypeptide comprising:
- a) amino acids 21-253 or 26-253 of SEQ ID NO;
2 and i) the amino acid at position 26 is Met;
ii) the amino acid at position 52 is Gly;
iii) the amino acid at position 59 is Gln;
or iv) the amino acid at position 150 is Leu;
or b) amino acids 20-253 or 26-253 of SEQ ID NO;
4 and i) the amino acid at position 26 is Met;
ii) the amino acid at position 52 is Gly;
iii) the amino acid at position 59 is Gln;
or iv) the amino acid at position 150 is Leu;
said composition further optionally comprising Apm1 (Adipose Most Abundant Gene Transcript
1) polypeptide.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.
-
Citations
54 Claims
-
1. A method of reducing body mass in an individual comprising administering to said individual a composition comprising a carrier and an Adipsin polypeptide comprising:
-
a) amino acids 21-253 or 26-253 of SEQ ID NO;
2 andi) the amino acid at position 26 is Met;
ii) the amino acid at position 52 is Gly;
iii) the amino acid at position 59 is Gln;
oriv) the amino acid at position 150 is Leu;
orb) amino acids 20-253 or 26-253 of SEQ ID NO;
4 andi) the amino acid at position 26 is Met;
ii) the amino acid at position 52 is Gly;
iii) the amino acid at position 59 is Gln;
oriv) the amino acid at position 150 is Leu;
said composition further optionally comprising Apm1 (Adipose Most Abundant Gene Transcript
1) polypeptide. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
-
-
11. A method of reducing body mass in an individual comprising administering to said individual a composition comprising a carrier and an Adipsin polypeptide:
-
a) comprising amino acids 1-228 of SEQ ID NO;
6;
b) consisting of amino acids 2-228 of SEQ ID NO;
6;
orc) comprising amino acids 2-228 of SEQ ID NO;
6, wherein position 27 is glycine, position 34 is arginine, or position 125 is leucine;
said composition further optionally comprising Apm1 (Adipose Most Abundant Gene Transcript
1) polypeptide. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
-
22. A method of reducing body mass in an individual comprising administering to said individual a composition comprising a carrier, Adipsin polypeptide comprising amino acids 2-228 of SEQ ID NO:
- 6 and Apm1 (Adipose Most Abundant Gene Transcript
1) polypeptide.
- 6 and Apm1 (Adipose Most Abundant Gene Transcript
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSerono Genetics Institute S.A. (Merck & Co., Inc.)
-
Original AssigneeGenset SA (Merck & Co., Inc.)
-
InventorsLucas, John, Briggs, Kristen
-
Primary Examiner(s)Cochrane Carlson, Karen
-
Assistant Examiner(s)Desai, Anand U
-
Application NumberUS10/202,676Publication NumberTime in Patent Office967 DaysField of Search514/12, 435/69.1, 435/320.1US Class Current514/4.8CPC Class CodesA61K 38/1709 from mammals
